Been waiting eagerly for Diaceutics trading update and it hasn't disappointed! 

Revenue ahead of consensus FCs +36% to £32.2m.

Adj EBITDA marginally ahead of FCs.

Returning to profitability this year.

ARR grew 23% to £16.8m. Recurring revenues now 55% of total revs.
#DXRX 1/2